Influence of alloxan-induced diabetes and selenite treatment on blood glucose and glutathione levels in mice.

Many clinical studies reported that diabetic patients had lower glutathione contents in erythrocytes or plasma. Recently, selenium, an essential trace element with well-known antioxidant characteristics, has been found to have insulin-mimetic properties. But seldom information is available about the influence of selenium on glutathione changes induced by diabetes mellitus in animals. Therefore, this study was designed to compare the impacts of selenite treatment on glutathione (GSH) levels of blood and tissues such as brain, kidney, liver, spleen and testis in mice. Four groups were used in this study: a control group, a diabetic group, a selenite-treated normal group and a selenite-treated diabetic group. Selenite was administered to the mice for 4 weeks with an oral dose of 2 mg kg(-1) day(-1) by gavage. The blood glucose level, and GSH level in blood and tissues were determined. The results show that the selenite-treated diabetic group had significantly lower blood glucose levels than the diabetic group. Moreover, alloxan-induced diabetes significantly decreased GSH levels in blood, kidney, liver and testis compared to the controls. Selenite treatment of the diabetic mice only improved the GSH levels in liver and brain. On the other hand, selenite administered to the normal mice reduced GSH levels in the liver compared to the controls. In conclusion, this study suggests that selenite treatment of diabetic mice with an effective dose would be beneficial for the antioxidant system of liver and brain although it exerts a toxic effect on the liver of normal mice.

New experimental observation on the relationship of selenium and diabetes mellitus.

Selenium shows insulin-mimic properties in vitro and in vivo. However, in this study, a high dose of 4 mg/kg/d selenite orally administered to the alloxan-induced diabetic Kun-Ming mice for 4 wk failed to reduce hyperglycemia. Se contents in plasma and tissues such as the liver, kidney, spleen, and brain were determined and the thiobarbituric acid-reactive substances (TBARS) levels were investigated. The results showed that alloxan-induced diabetes did not cause a significant decrease in Se levels in plasma and the above tissues compared to the normal control, but selenite treatment significantly increased Se levels in plasma, liver, and brain of the selenite-treated diabetic mice compared to the nontreated diabetic mice. In addition, selenite treatment for diabetic mice reduced the TBARS levels in red blood cells (RBCs) compared to the normal and improved the glutathione peroxidase (GSH-Px) levels in RBCs significantly compared to the diabetic control. In conclusion, this study demonstrated that although oral administration of a high dose of selenite had no hypoglycemic effect on diabetic mice in 4 wk, selenite treatment still maintained the antioxidant beneficial effect on the diabetic mice. This study shed more light on the relationship between Se and diabetes.

Hypoglycaemic effect of a novel insulin buccal formulation on rabbits.

Transmucosal delivery is a suitable route for insulin non-injection administration. In this study, the hypoglycaemic effect of INSULIN BUCCAL SPRAY (IBS), a formulation with soybean lecithin and propanediol combined as absorption enhancer for insulin on diabetic rabbits and rats, were investigated. The hypoglycaemic rate was calculated and the pharmacodynamics and pharmacokinetics of the formulation in rabbits were studied. The results show that when the diabetic rabbits were administrated with IBS in dosages of 0.5, 1.5 and 4.5Ukg(-1), the blood glucose level decreased significantly compared with that of the control group and the hypoglycaemic effect lasted over 5h. The blood glucose decreasing rates are 22.4, 48.1 and 53.5%, respectively. The average bioavailability of IBS by buccal delivery versus subcutaneous injection is 29.2%. Meanwhile, the diabetic rats were administrated with IBS in dosages of 1.0, 3.0 and 9.0Ukg(-1), the blood glucose level decreased significantly compared with that of the control group and the hypoglycaemic effect lasted over 4h. The blood glucose decreasing rates are 24.6, 47.5 and 59.6%, respectively. Furthermore, the penetration of fluorescein isothiocyanate (FITC)-labelled insulin through rabbit buccal mucosa was investigated by scanning the distribution of the fluorescent probe in the epithelium using confocal laser scanning microscopy. The results revealed that FITC-insulin can pass through the buccal mucosa promoted by the enhancer and the passage of insulin across the epithelium includes both intracellular and paracellular routes. From the rabbit and rat experimental results showed that IBS is an effective buccal delivery system, which is promising for clinical trial and the future clinical application.